Pharmacists Weigh Promise and Challenges of Finerenone for Patients With HFpEF
Pharmacy Times
JULY 24, 2025
Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Barriers to finerenone integration include cost, access, and existing MRA underutilization, with pharmacists crucial in educating prescribers and patients.
Let's personalize your content